CLINICAL ROLE -
Clostridium Difficile Infection Associated With Higher Mortality Rates in Intestinal Transplant Recipients
An organ transplant is a known risk factor for C. difficile infection, however, data are lacking on how the infection affects those who underwent an intestinal transplant.
January 2023 Rx Product News
Zilucoplan is among highlighted products of the month.
FDA Approves Zanubrutinib for Treatment of CLL or SLL
Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa; BeiGene USA, Inc) approved for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.
Deucravacitinib Found Superior to Apremilast in Treating Plaque Psoriasis
Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 inhibitor that inhibits cytokine signaling in psoriasis pathogenesis.
'Nocebo' Effect May Influence Outcomes After Switching to a Biosimilar
Research shows that some unsuccessful switches from reference products to biosimilars may be attributed to patient perceptions of reduced efficacy and safety.
RT-PCR Testing May Improve Detection of C. Difficile in Hospital Settings
Molecular methods such as polymerase chain reaction show promise in monitoring the patient environment in hospitals and could help to provide reassurance prior to admission.
January 2023 Over-the-Counter Product News
Products range from natural eye relief to sleep aid.
Biosimilar Shows Comparable Safety, Efficacy to Reference Product in Patients With RA
YLB113 (Nepexto) produced significantly lower injection site reactions and injection site erythema compared with etanercept in patients with rheumatoid arthritis.
Study Evaluates Impact of CDI on Patients With Cystic Fibrosis
Patients with cystic fibrosis are typically administered antibiotics throughout their lives, which can increase the risk for C difficile infections.
Wearable Device Accurately Tracks Heart Failure Progression
Approximately half of patients with heart failure do not require an implantable monitoring device or do not qualify for thoracic monitoring.
FDA Grants EUA to Mpox PCR Assay Test
There have been more than 80,000 monkeypox cases reported worldwide.
Rates of Hand Eczema Among Health Care Workers Grew During COVID-19 Pandemic
Greater prevalence of hand eczema among health care professionals working in COVID-19 units linked to increased hand sanitation habits.
Improved Access to Direct-acting Antivirals Lowers Hepatitis C Incidence Rates
Study finds a strong decline in hepatitis C incidence in the years immediately following broad access to direct-acting antiviral drugs.
Study Outlines Dupilumab Prescribing in New Systemic Therapy Users for Atopic Dermatitis
Clinical trials show that patients with atopic dermatitis experienced improved symptoms with dupilumab starting at 8 weeks, with maximum effect around 12 weeks.
December Rx Product News
Products include a vaccine for meningococcal disease and a new type of COVID-19 test.
December OTC Product News
Products range from acne treatment to cough relief.
FDA Approves Cariprazine for Major Depressive Disorder
Cariprazine (Vraylar; AbbVie, Gedeon Richter) is indicated as an adjunctive therapy to antidepressants for treating adult patients with major depressive disorder.
FDA Approves Adalimumab Biosimilar for Plaque Psoriasis, Other Chronic Conditions
Adalimumab-aacf (Idacio) is indicated for chronic conditions such as rheumatoid arthritis, plaque psoriasis, ulcerative colitis, psoriatic arthritis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
Celiac Disease May Increase the Risk of Developing Psoriasis
Study finds gluten-free diets may play an important role in the causality of celiac disease on the development of psoriasis.
FDA Grants Accelerated Approval to Adagrasib for KRAS-G12C-Mutated NSCLC
Adagrasib (Krazati; Mirati Therapeutics, Inc) approved for adults with KRAS-G12C-mutated locally advanced or metastatic non-small cell lung cancer as determined by an FDA-approved test.
Regular Exercise Improves Outcomes in Patients With Colorectal Cancer
Regular physical activity helps to facilitate a healthy gut microbiome and lowers inflammation, which were observed in patients independent of body mass index.
Study to Evaluate Efficacy of Device That Closes Patent Foramen Ovale in Treating Migraine
Prior research indicates a platelet-based connection between migraine and the patent foramen ovale.
Study Highlights Importance of Zoster Vaccination for Older Adults
Herpes zoster and postherpetic neuralgia can cause a significant health burden among adults 65 years of age and older.
Dapagliflozin Improves Outcomes in Patients With Chronic Kidney Disease Regardless of Presence of Diabetes
Dapagliflozin (Farxiga) found effective in lowering the risk of hospitalization for patients with chronic kidney disease, with or without a diagnosis of type 2 diabetes, and increased the number of days alive and out of the hospital.
Novel Compounds Show Potential for Treating Anxiety Disorders With Fewer Adverse Effects
Lead compounds may lower the risk of abuse and other adverse effects compared with other drugs currently being evaluated for mental health disorders, such as MDMA.
Durvalumab Improves Survival in Advanced Biliary Tract Cancer
Study findings may make durvalumab plus chemotherapy a new standard of care option for patients with advanced biliary tract cancer.
Research Supports Efficacy, Safety of Palivizumab Preventing Lower Respiratory Tract Infections by RSV
Palivizumab is a humanized monoclonal antibody approved by the FDA to prevent serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children.
Whole Body Scans May Help Reveal Which Patients Will Respond to Immune Checkpoint Inhibitors
The presence of CD8+ cells may help predict outcomes for patients administered immune checkpoint inhibitors.
Zavegepant Nasal Spray Shows Promise in Acute Treatment of Migraine
Zavegepant could become the first intranasal drug that targets CGRP in migraine sufferers to gain FDA approval.
Treatment With Atrasentan Improves Albuminuria in Patients With Chronic Kidney Disease, Diabetes
Atrasentan has been found to lower albuminuria, which correlates with reductions in low-density lipoprotein cholesterol and triglycerides.
2 Clarke Drive Cranbury, NJ 08512